Eli Lilly and Company has received FDA approval for its IL-13 inhibitor, Ebglyss (lebrikizumab), to treat moderate-to-severe atopic dermatitis (eczema) in adults and children aged 12 and above. Ebglyss joins a growing list of new drug approvals for Lilly, including Mounjaro, Zepbound, Omvoh, and Jaypirca, all contributing to the company’s strong financial performance. The company’s stock has outperformed the industry, sector, and S&P 500, with its new drugs driving significant revenue growth.